Андрология и генитальная хирургия. 2016; 17: 112-118
Возможности применения растительных препаратов в стероидогенезе у мужчин с гипогонадизмом
https://doi.org/10.17650/2070-9781-2016-17-2-112-118Аннотация
Многокомпонентный препарат Тестогенон® содержит витамины и биологически активные вещества, являющиеся обязательным кофакторным элементом в биохимических реакциях стероидогенеза у мужчин. Безопасность и фармакологическая эффективность этого средства подтверждены в экспериментальных исследованиях. В условиях дефицита витаминов и микроэлементов применение препарата Тестогенон® в составе комплексной терапии патогенетически обосновано и клинически оправдано.
Список литературы
1. Corradi P. F., Corradi R. B., Greene L. W. Physiology of the hypothalamic pituitary gonadal axis in the male. Urol Clin North Am 2016;43(2):151–62.
2. Fernández-Miró M., Chillarón J. J., Pedro-Botet J. Testosterone deficiency, metabolic syndrome and diabetes mellitus. Med Clin (Barc) 2016;146(2):69–73.
3. Никитин А. И. Гормоноподобные ксено биотики и их роль в репродуктивной функции человека. Медицинская экология 2006;(1):9–16. [Nikitin А. I. Hormone-like xenobiotics and its role in the human reproductive function. Меditsinskaya ekologiya = Меdical Ecology 2006;(1):9–16. (In Russ.)].
4. Закревский В. В., Лифляндский В. Г. Алиментарная профилактика негативных последствий избыточного потребления пива мужчинами. Справочник врача общей практики 2015;(11):20–4. [Zakrevskiy V. V., Liflyandskiy V. G. Аlimentary prophylactics of negative consequences of the excessive beer consumption by men. Spravochnik vracha obshchey praktiki = General Physician’s Reference Book 2015;(11):20–4. (In Russ.)].
5. Калинченко С. Ю., Тюзиков И. А., Ворслов Л. О., Тишова Ю. А. Ожирение, инсулинорезистентность и репродуктивное здоровье мужчины: патогенетические взаимодействия и современная патогенетическая терапия. Эффективная фармакотерапия 2015;(27):66–79. [Kalinchenko S. Yu., Тyuzikov I. А., Vorslov L. О., Тishovа Yu. А. Оbesity, insulin resistance and men’s reproductive health: pathogenic interactions and modern pathogenic therapy. Effektivnaya farmakoterapiya = Effective Pharmaco therapy 2015;(27):66–79. (In Russ.)].
6. Люненфельд Б., Мсхалая Г.Ж., Зицман Н. и др. Рекомендации по диагностике, лечению и мониторированию гипогонадизма у мужчин. Эффективная фармакотерапия 2015;(27):6–20. [Lyunenfel’d B., Мskhalaya G. Zh., Zytsman N. et al. Recommendations on the diagnostics, treatment and monitoring of men’s hypogonadism. Effektivnaya farmakoterapiya = Effective Pharmacotherapy 2015;(27):6–20. (In Russ.)].
7. Corona G., Rastrelli G., Maseroli E. et al. Testosterone replacement therapy and cardiovascular risk: a review. World J Mens Health 2015;33(3):130–42.
8. Lunenfeld B., Mskhalaya G., Zitzerman M. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in man. Aging Male 2015;18(1):5–15.
9. Havilland T. N., Parrish L. Ch. An early 20th-century testicular transplantation. Trans Stud Coll Physicians Phila 1971;38(4):231–4.
10. The New York Times. June 18, 1922.
11. Воронов С. Rejuvenation by Crafting. Ed. by F. F. Imyanitoff. Adelphi, 1925. Pp. 57–67. [Voronov S. Rejuvenation by Crafting. Ed. by F. F. Imyanitoff. Adelphi, 1925. Pp. 57–67. (In Russ.)].
12. Дедов И. И., Калинченко С. Ю. Возрастной андрогенный дефицит у мужчин. М.: Практическая медицина, 2006. 240 с. [Dedov I. I., Kalinchenkо S. Yu. Androgen deficiency of the aging male. Мoscow: Practicheskaya Meditsina, 2006. 240 p. (In Russ.)].
13. Калинченко С. Ю., Тюзиков И. А. Практическая андрология. М.: Практическая медицина, 2009. 398 с. [Kalinchenko S. Yu., Тyuzikov I. А. Practical andrology. Мoscow: Practicheskaya Meditsina, 2009. 398 p. (In Russ.)].
14. Baillargeon J., Urban R. J., Mergenthaler A. et al. Risk of venous thromboembolism in men receiving testosterone therapy. Mayo Clin Proc 2015;90(8):1038–45.
15. Diemer T., Hauptmann A., Wagenlehner F. M. Testosterone therapy. Urologe A 2016;55(4):539–50.
16. Gabrielsen J. S., Najari B. B., Alukal J. P., Eisenberg M. L. Trends in testosterone prescription and public health concerns. Urol Clin North Am 2016;43(2):261–71.
17. Berkseth K. E., Thirumalai A., Amory J. K. Pharmacologic therapy in men’s health: hypogonadism, erectile dysfunction, and benign prostatic hyperplasia. Med Clin North Am 2016;100(4):791–805.
18. Fiers T., Kaufman J. M. Management of hypogonadism: is there a role for salivary testosterone. Endocrine 2015;50(1):1–3.
19. Hassan J., Barkin J. Testosterone deficiency syndrome: benefits, risks, and realities associated with testosterone replacement therapy. Can J Urol 2016;23(Suppl 1):20–30.
20. Ross A., Bhasin S. Hypogonadism: its prevalence and diagnosis. Urol Clin North Am 2016;43(2):163–76.
21. Millar A. C., Lau A. N., Tomlinson G. et al. Predicting low testosterone in aging men: a systematic review. CMAJ 2016.
22. Ершов Ю. А. Биохимия человека. М.: Юрайт, 2016. 376 с. [Еrshov Yu. А. Human biochemistry. Мoscow: Yurayt, 2016. 376 p. (In Russ.)].
23. Батько А. Б. Фармаконутритивная поддержка пациентов с доброкачественной гиперплазией предстательной железы и хроническим простатитом. Андрология и генитальная хирургия 2015;(1):83–6. [Bat’ko A. B. Pharmacological and nutritive support of patients with benign prostatic hyperplasia and chronic prostatitis. Andrologiya i genital’naya khirurgiya = Andrology and Genital Surgery 2015;(1):83–6. (In Russ.)].
24. Лысиков Ю. А. Роль и физиологические основы обмена макро- и микроэлементов в питании человека. Экспериментальная и клиническая гастроэнтерология 2009; (2):120–31. [Lysikov Yu. А. Role and physiological elements of macro- and microelements exchange in the human nutrition. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology 2009;(2):120–31. (In Russ.)].
25. Нотова С. В., Элементный статус человека – возрастной аспект. Гигиена окружающей и производственной среды 2005;1(6):91–3. [Notovа S. V., Human elemental status – age-related aspect. Gigiena okruzhayushchey i proizvodstvennoy sredy = Environmental and Industrial Hygiene 2005;1(6):91–3. (In Russ.)].
26. Методические рекомендации МР 2.3.1.2432–08. Нормы физиологических потребностей в энергии и пищевых веществах для различных групп населения Российской Федерации (утверждено Роспотребнадзором 18.12.2008). [Меthodic Recommendations 2.3.1.2432–08. Norms of physiological needs for energy and nutrient materials for different population groups of the Russian Federation (approved by Rospotrebnadzor 18.12.2008). (In Russ.)].
27. Шабров А. В., Дадали В. А., Макаров В. Г. Биохимические основы действия микронутриентов пищи. М.: Аввалон, 2003. 150 с. [Shabrov А. V., Dadali V. А., Маkarov V. G. Biochemical elements of the action of food’s micronutrients. Мoscow: Аvvalon, 2003. 150 p. (In Russ.)].
28. Gropper S. S., Smith J. L. Advanced nutrition and human metabolism. 6th edn. Wadsworth, 2013. 608 p.
29. Whitney E., Rolfes S. R. Understanding nutrition. 13th edn. Wadsworth, 2013. 975 p.
30. Кадири Т. Р., Сафаров И., Ибодуллоев И. Препарат Верона в комплексном лечении бесплодия. Вестник последипломного образования в сфере здравоохранения 2012; (3):131–2. [Kadiri Т. R., Safarov I., Ibodulloev И. Verona in the comprehensive treatment of infertility. Vestnik poslediplomnogo obrazovaniya v sfere zdravookhraneniya = Journal of Postgraduate Education in the Feld of Public Health 2012;(3):131–2. (In Russ.)].
31. Лифляндский В. Г. Патогенетическое обоснование биологически активной добавки Тестогенон для комплексного воздействия на мужскую репродуктивную систему. Андрология и генитальная хирургия 2015;(2):61–4. [Liflyandskiy V. G. Pathogeneti c justification of dietary supplement Testogenon for complex impact on men’s reproductive system. Andrologiya i genital’naya khirurgiya = Andrology and Genital Surgery 2015;(2):61–4. (In Russ.)].
32. Никитин Д. М. Возможности препарата Трибестан в поддержании мужского репродуктивного здоровья. Репродуктивное здоровье в Беларуси 2011;(5):68–74. [Nikitin D. М. Tribestan potentialities for the maintenance of men’s reproductive health. Reproduktivnoe zdorov’e v Belarusi = Reproductive Health in Belarus 2011;(5):68–74 (In Russ.)].
33. Никитин Д. М. Севастьянов В. С., Гринюк Н. К. Применение препарата Трибестан в лечении основных проблем мужского репродуктивного здоровья. Репродуктивное здоровье. Восточная Европа 2012;(1):136–43. [Nikitin D. М., Sevast’yanov V. S., Grinyuk N. K. Tribestan application in the treatment of basic men’s reproductive health problems. Reproduktivnoe zdorov’e. Vostochnaya Evropa = Reproductive Health. Eastern Europe 2012;(1):136–43. (In Russ.)].
34. Попов С. В. Применение Трибестана в лечении андрологических заболеваний. Русский медицинский журнал 2011;(16):1013–7. [Popov S. V. Tribestan application in the treatment of andrologic diseases. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2011;(16):1013–7. (In Russ.)].
35. Целухин И. И. Применение препарата Верона в комплексной терапии мужского бесплодия. Андрология и генитальная хирургия 2011;(2):73–6. [Tselukhin I. I. Verona application in the comprehensive treatment of men’s infertility. Andrologiya i genital’naya khirurgiya = Andrology and Genital Surgery 2011;(2):73–6. (In Russ.)].
36. Вислобоков А. И. К вопросу о цитофармакологии. Обзоры по клинической фармакологии и лекарственной терапии 2009;(1):61–70. [Vislobokov А. I. On the cytopharmacology issue. Obzory po klini cheskoy farmakologii i lekarstvennoy terapii = Reviews in Clinical Pharmacology and Pharmaceutical Therapy 2009;(1):61–70. (In Russ.)].
37. Desroches B., Kohn T. P., Welliver C. Testosterone therapy in the new era of food and drug administration oversight. Transl Andro Urol 2016;5(2):207–12.
38. Доклиническое изучение острой и субхронической токсичности биологически активной добавки (БАД) к пище «ТестогенонТМ», капсулы, 0,5 г, производства ООО «ВИС». Отчет ФГБУ «Институт токсикологии ФМБА». СПб., 2012. 29 с. [Pre-clinical studies of the acute and sub-chronic toxicity of TestogenonТМ dietary supplement, capsules 0,5 g, manufactured by VIS. Report of FMBA Toxicology Institute. Saint Petersburg, 2012. 29 p. (In Russ.)].
39. Доклиническое изучение специфической фармакологической активности биологически активной добавки (БАД) к пище «ТестогенонТМ», капсулы, 0,5 г, производства ООО «ВИС». Отчет ФГБУ «Институт токсикологии ФМБА». СПб., 2012. 15 с. [Pre-clinical studies of the specific pharmacologic activity of the TestogenonТМ dietary supplement, capsules 0,5 g, manufactured by VIS. Report of FMBA Toxicology Institute. Saint Petersburg, 2012. 15 p. (In Russ.)].
Andrology and Genital Surgery. 2016; 17: 112-118
Possibility of the use of herbal medicines in steroidogenesis in hypogonadal men
https://doi.org/10.17650/2070-9781-2016-17-2-112-118Abstract
Multi-drug Testogenon® contains vitamins and biologically active substances, which are cofactor binding element in biochemical reactions steroidogenesis in males. Harmlessness and pharmacological effectiveness of the drug was confirmed in experimental studies. In the context of micronutrient vitamin deficiency use of the drug Testogenon® in the complex therapy pathogenetically substantiated and clinically justified.
References
1. Corradi P. F., Corradi R. B., Greene L. W. Physiology of the hypothalamic pituitary gonadal axis in the male. Urol Clin North Am 2016;43(2):151–62.
2. Fernández-Miró M., Chillarón J. J., Pedro-Botet J. Testosterone deficiency, metabolic syndrome and diabetes mellitus. Med Clin (Barc) 2016;146(2):69–73.
3. Nikitin A. I. Gormonopodobnye kseno biotiki i ikh rol' v reproduktivnoi funktsii cheloveka. Meditsinskaya ekologiya 2006;(1):9–16. [Nikitin A. I. Hormone-like xenobiotics and its role in the human reproductive function. Meditsinskaya ekologiya = Medical Ecology 2006;(1):9–16. (In Russ.)].
4. Zakrevskii V. V., Liflyandskii V. G. Alimentarnaya profilaktika negativnykh posledstvii izbytochnogo potrebleniya piva muzhchinami. Spravochnik vracha obshchei praktiki 2015;(11):20–4. [Zakrevskiy V. V., Liflyandskiy V. G. Alimentary prophylactics of negative consequences of the excessive beer consumption by men. Spravochnik vracha obshchey praktiki = General Physician’s Reference Book 2015;(11):20–4. (In Russ.)].
5. Kalinchenko S. Yu., Tyuzikov I. A., Vorslov L. O., Tishova Yu. A. Ozhirenie, insulinorezistentnost' i reproduktivnoe zdorov'e muzhchiny: patogeneticheskie vzaimodeistviya i sovremennaya patogeneticheskaya terapiya. Effektivnaya farmakoterapiya 2015;(27):66–79. [Kalinchenko S. Yu., Tyuzikov I. A., Vorslov L. O., Tishova Yu. A. Obesity, insulin resistance and men’s reproductive health: pathogenic interactions and modern pathogenic therapy. Effektivnaya farmakoterapiya = Effective Pharmaco therapy 2015;(27):66–79. (In Russ.)].
6. Lyunenfel'd B., Mskhalaya G.Zh., Zitsman N. i dr. Rekomendatsii po diagnostike, lecheniyu i monitorirovaniyu gipogonadizma u muzhchin. Effektivnaya farmakoterapiya 2015;(27):6–20. [Lyunenfel’d B., Mskhalaya G. Zh., Zytsman N. et al. Recommendations on the diagnostics, treatment and monitoring of men’s hypogonadism. Effektivnaya farmakoterapiya = Effective Pharmacotherapy 2015;(27):6–20. (In Russ.)].
7. Corona G., Rastrelli G., Maseroli E. et al. Testosterone replacement therapy and cardiovascular risk: a review. World J Mens Health 2015;33(3):130–42.
8. Lunenfeld B., Mskhalaya G., Zitzerman M. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in man. Aging Male 2015;18(1):5–15.
9. Havilland T. N., Parrish L. Ch. An early 20th-century testicular transplantation. Trans Stud Coll Physicians Phila 1971;38(4):231–4.
10. The New York Times. June 18, 1922.
11. Voronov S. Rejuvenation by Crafting. Ed. by F. F. Imyanitoff. Adelphi, 1925. Pp. 57–67. [Voronov S. Rejuvenation by Crafting. Ed. by F. F. Imyanitoff. Adelphi, 1925. Pp. 57–67. (In Russ.)].
12. Dedov I. I., Kalinchenko S. Yu. Vozrastnoi androgennyi defitsit u muzhchin. M.: Prakticheskaya meditsina, 2006. 240 s. [Dedov I. I., Kalinchenko S. Yu. Androgen deficiency of the aging male. Moscow: Practicheskaya Meditsina, 2006. 240 p. (In Russ.)].
13. Kalinchenko S. Yu., Tyuzikov I. A. Prakticheskaya andrologiya. M.: Prakticheskaya meditsina, 2009. 398 s. [Kalinchenko S. Yu., Tyuzikov I. A. Practical andrology. Moscow: Practicheskaya Meditsina, 2009. 398 p. (In Russ.)].
14. Baillargeon J., Urban R. J., Mergenthaler A. et al. Risk of venous thromboembolism in men receiving testosterone therapy. Mayo Clin Proc 2015;90(8):1038–45.
15. Diemer T., Hauptmann A., Wagenlehner F. M. Testosterone therapy. Urologe A 2016;55(4):539–50.
16. Gabrielsen J. S., Najari B. B., Alukal J. P., Eisenberg M. L. Trends in testosterone prescription and public health concerns. Urol Clin North Am 2016;43(2):261–71.
17. Berkseth K. E., Thirumalai A., Amory J. K. Pharmacologic therapy in men’s health: hypogonadism, erectile dysfunction, and benign prostatic hyperplasia. Med Clin North Am 2016;100(4):791–805.
18. Fiers T., Kaufman J. M. Management of hypogonadism: is there a role for salivary testosterone. Endocrine 2015;50(1):1–3.
19. Hassan J., Barkin J. Testosterone deficiency syndrome: benefits, risks, and realities associated with testosterone replacement therapy. Can J Urol 2016;23(Suppl 1):20–30.
20. Ross A., Bhasin S. Hypogonadism: its prevalence and diagnosis. Urol Clin North Am 2016;43(2):163–76.
21. Millar A. C., Lau A. N., Tomlinson G. et al. Predicting low testosterone in aging men: a systematic review. CMAJ 2016.
22. Ershov Yu. A. Biokhimiya cheloveka. M.: Yurait, 2016. 376 s. [Ershov Yu. A. Human biochemistry. Moscow: Yurayt, 2016. 376 p. (In Russ.)].
23. Bat'ko A. B. Farmakonutritivnaya podderzhka patsientov s dobrokachestvennoi giperplaziei predstatel'noi zhelezy i khronicheskim prostatitom. Andrologiya i genital'naya khirurgiya 2015;(1):83–6. [Bat’ko A. B. Pharmacological and nutritive support of patients with benign prostatic hyperplasia and chronic prostatitis. Andrologiya i genital’naya khirurgiya = Andrology and Genital Surgery 2015;(1):83–6. (In Russ.)].
24. Lysikov Yu. A. Rol' i fiziologicheskie osnovy obmena makro- i mikroelementov v pitanii cheloveka. Eksperimental'naya i klinicheskaya gastroenterologiya 2009; (2):120–31. [Lysikov Yu. A. Role and physiological elements of macro- and microelements exchange in the human nutrition. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology 2009;(2):120–31. (In Russ.)].
25. Notova S. V., Elementnyi status cheloveka – vozrastnoi aspekt. Gigiena okruzhayushchei i proizvodstvennoi sredy 2005;1(6):91–3. [Notova S. V., Human elemental status – age-related aspect. Gigiena okruzhayushchey i proizvodstvennoy sredy = Environmental and Industrial Hygiene 2005;1(6):91–3. (In Russ.)].
26. Metodicheskie rekomendatsii MR 2.3.1.2432–08. Normy fiziologicheskikh potrebnostei v energii i pishchevykh veshchestvakh dlya razlichnykh grupp naseleniya Rossiiskoi Federatsii (utverzhdeno Rospotrebnadzorom 18.12.2008). [Methodic Recommendations 2.3.1.2432–08. Norms of physiological needs for energy and nutrient materials for different population groups of the Russian Federation (approved by Rospotrebnadzor 18.12.2008). (In Russ.)].
27. Shabrov A. V., Dadali V. A., Makarov V. G. Biokhimicheskie osnovy deistviya mikronutrientov pishchi. M.: Avvalon, 2003. 150 s. [Shabrov A. V., Dadali V. A., Makarov V. G. Biochemical elements of the action of food’s micronutrients. Moscow: Avvalon, 2003. 150 p. (In Russ.)].
28. Gropper S. S., Smith J. L. Advanced nutrition and human metabolism. 6th edn. Wadsworth, 2013. 608 p.
29. Whitney E., Rolfes S. R. Understanding nutrition. 13th edn. Wadsworth, 2013. 975 p.
30. Kadiri T. R., Safarov I., Ibodulloev I. Preparat Verona v kompleksnom lechenii besplodiya. Vestnik poslediplomnogo obrazovaniya v sfere zdravookhraneniya 2012; (3):131–2. [Kadiri T. R., Safarov I., Ibodulloev I. Verona in the comprehensive treatment of infertility. Vestnik poslediplomnogo obrazovaniya v sfere zdravookhraneniya = Journal of Postgraduate Education in the Feld of Public Health 2012;(3):131–2. (In Russ.)].
31. Liflyandskii V. G. Patogeneticheskoe obosnovanie biologicheski aktivnoi dobavki Testogenon dlya kompleksnogo vozdeistviya na muzhskuyu reproduktivnuyu sistemu. Andrologiya i genital'naya khirurgiya 2015;(2):61–4. [Liflyandskiy V. G. Pathogeneti c justification of dietary supplement Testogenon for complex impact on men’s reproductive system. Andrologiya i genital’naya khirurgiya = Andrology and Genital Surgery 2015;(2):61–4. (In Russ.)].
32. Nikitin D. M. Vozmozhnosti preparata Tribestan v podderzhanii muzhskogo reproduktivnogo zdorov'ya. Reproduktivnoe zdorov'e v Belarusi 2011;(5):68–74. [Nikitin D. M. Tribestan potentialities for the maintenance of men’s reproductive health. Reproduktivnoe zdorov’e v Belarusi = Reproductive Health in Belarus 2011;(5):68–74 (In Russ.)].
33. Nikitin D. M. Sevast'yanov V. S., Grinyuk N. K. Primenenie preparata Tribestan v lechenii osnovnykh problem muzhskogo reproduktivnogo zdorov'ya. Reproduktivnoe zdorov'e. Vostochnaya Evropa 2012;(1):136–43. [Nikitin D. M., Sevast’yanov V. S., Grinyuk N. K. Tribestan application in the treatment of basic men’s reproductive health problems. Reproduktivnoe zdorov’e. Vostochnaya Evropa = Reproductive Health. Eastern Europe 2012;(1):136–43. (In Russ.)].
34. Popov S. V. Primenenie Tribestana v lechenii andrologicheskikh zabolevanii. Russkii meditsinskii zhurnal 2011;(16):1013–7. [Popov S. V. Tribestan application in the treatment of andrologic diseases. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2011;(16):1013–7. (In Russ.)].
35. Tselukhin I. I. Primenenie preparata Verona v kompleksnoi terapii muzhskogo besplodiya. Andrologiya i genital'naya khirurgiya 2011;(2):73–6. [Tselukhin I. I. Verona application in the comprehensive treatment of men’s infertility. Andrologiya i genital’naya khirurgiya = Andrology and Genital Surgery 2011;(2):73–6. (In Russ.)].
36. Vislobokov A. I. K voprosu o tsitofarmakologii. Obzory po klinicheskoi farmakologii i lekarstvennoi terapii 2009;(1):61–70. [Vislobokov A. I. On the cytopharmacology issue. Obzory po klini cheskoy farmakologii i lekarstvennoy terapii = Reviews in Clinical Pharmacology and Pharmaceutical Therapy 2009;(1):61–70. (In Russ.)].
37. Desroches B., Kohn T. P., Welliver C. Testosterone therapy in the new era of food and drug administration oversight. Transl Andro Urol 2016;5(2):207–12.
38. Doklinicheskoe izuchenie ostroi i subkhronicheskoi toksichnosti biologicheski aktivnoi dobavki (BAD) k pishche «TestogenonTM», kapsuly, 0,5 g, proizvodstva OOO «VIS». Otchet FGBU «Institut toksikologii FMBA». SPb., 2012. 29 s. [Pre-clinical studies of the acute and sub-chronic toxicity of TestogenonTM dietary supplement, capsules 0,5 g, manufactured by VIS. Report of FMBA Toxicology Institute. Saint Petersburg, 2012. 29 p. (In Russ.)].
39. Doklinicheskoe izuchenie spetsificheskoi farmakologicheskoi aktivnosti biologicheski aktivnoi dobavki (BAD) k pishche «TestogenonTM», kapsuly, 0,5 g, proizvodstva OOO «VIS». Otchet FGBU «Institut toksikologii FMBA». SPb., 2012. 15 s. [Pre-clinical studies of the specific pharmacologic activity of the TestogenonTM dietary supplement, capsules 0,5 g, manufactured by VIS. Report of FMBA Toxicology Institute. Saint Petersburg, 2012. 15 p. (In Russ.)].
